CSL (OTCMKTS:CSLLY) Shares Gap Up – Time to Buy?

Posted by George Bondi on Oct 14th, 2026

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report) gapped up prior to trading on Wednesday. The stock had previously closed at $32.17, but opened at $33.60. CSL shares last traded at $32.2450, with a volume of 874 shares changing hands.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CSLLY. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a research report on Friday, August 7th. Royal Bank Of Canada upgraded CSL from a “hold” rating to a “moderate buy” rating in a report on Tuesday, September 15th. One research analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, CSL has a consensus rating of “Hold”.

View Our Latest Analysis on CSLLY

CSL Trading Down 0.3%

The stock’s 50-day simple moving average is $29.82 and its 200 day simple moving average is $24.04. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.21 and a quick ratio of 0.97.

CSL Company Profile

(Get Free Report)

CSL Limited is an Australia-based biopharmaceutical company that develops and manufactures medicines, vaccines and other healthcare products. The company serves patients, healthcare providers and public health systems worldwide through its major businesses, CSL Behring, CSL Seqirus and CSL Vifor.

CSL Behring specializes in plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders, hereditary angioedema and other rare or serious conditions. CSL Seqirus develops and supplies influenza vaccines and other vaccines, while CSL Vifor focuses on treatments for iron deficiency, kidney disease and related conditions.

The company traces its origins to Commonwealth Serum Laboratories, which was established by the Australian government in 1916.